Indication
Diffuse Large B-Cell Lymphoma (DLBCL)
2 clinical trials
2 products
1 drug
Product
ATA3219Clinical trial
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
GolcadomideDrug
Varlilumab